• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Aug 29, 2023
Distillery Therapeutics

Microbial DPP-4 inhibitor for Type II diabetes

Read More
BioCentury | Aug 8, 2023
Product Development

CVOT data for Novo’s Wegovy set bar for health benefit in obesity

Big market cap gains for Novo, Lilly as GLP-1 cuts CV risk by 20%
Read More
BioCentury | May 3, 2023
Distillery Therapeutics

Inhibiting DPP-4 to treat AML

Read More
BioCentury | Feb 19, 2021
Product Development

What works, what doesn’t and what’s next for COVID-19: Data Byte

A COVID-19 report card and look ahead to the next late-stage readouts
Read More
BioCentury | Feb 6, 2020
Deals

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

Recent and future BD will help drive Merck's innovation, while slower-growing businesses are headed for a new entity
Read More
BioCentury | Jan 29, 2020
Product Development

Industry leaders applaud CVS zero co-pay diabetes drug access

CVS is answering the call to decrease the cost burden of diabetes medications on patients
Read More
BioCentury | Dec 21, 2019
Politics, Policy & Law

U.S. drug industry hopes China deal ends stealth attack on IP

Innovators hope trade deal stops China's stealth war on IP
Read More
BioCentury | Nov 13, 2019
Clinical News

Hua Phase III diabetes data make good on glucokinase but disappoint investors

Hua’s glucokinase activator notches a Phase III win for the long-pursued target
Read More
BioCentury | Sep 25, 2019
Company News

Sept. 24 Company Quick Takes: FDA approves smallpox vaccine; plus Epidyolex, Vitrakvi, Oral semaglutide, Takeda-Evotec, Guerbet-IBM Watson

Read More
BioCentury | Aug 2, 2019
Financial News

Aug. 2 Financial Quick Takes: Rakuten Medical bags another $100M; plus CGeneTech, Zecen, Qyuns and more

Read More
Items per page:
1 - 10 of 99